- Extracellular vesicles (EVs)-based liquid biopsies, offering non-invasive molecular diagnostics, are becoming increasingly crucial in modern healthcare due to their ability to capture disease-specific biomarkers in real-time from various body fluids. This technology is particularly valued for its utility in cancer detection, neurological disorders, and cardiovascular conditions
- The demand for EV-based liquid biopsy solutions is primarily driven by the rising prevalence of chronic diseases, growing adoption of personalized medicine, and increasing need for early, non-invasive diagnostic tools that can monitor disease progression and response to therapy
- North America dominated the extracellular vesicles based liquid biopsy market with the largest revenue share of 43.25% in 2024, fueled by robust R&D investment, early adoption of cutting-edge diagnostic technologies, and strong collaboration between academic institutions and biotech companies. The U.S., in particular, leads the region with a growing number of clinical studies and product developments aimed at validating EV-based diagnostics in oncology and other diseases
- Asia-Pacific is expected to witness the fastest growth in the extracellular vesicles based liquid biopsy market, driven by increasing healthcare expenditure, expanding cancer patient pool, and rapid improvements in biotechnology infrastructure across countries such as China, India, and Japan
- The Isolation segment dominated the extracellular vesicles based liquid biopsy market with a market share of 58.7% in 2024, attributed to its critical role in obtaining high-purity extracellular vesicles (EVs), which ensures superior sample quality and enhances downstream diagnostic accuracy. The increasing demand for standardized and efficient isolation methods across research and clinical applications is further propelling the dominance of this segment in the global extracellular vesicles based liquid biopsy market
